Vensana Capital—an independent, medtech-focused venture capital investment firm supported by Versant Ventures—has launched with a $225 million fund and ambitions to support new breakthroughs in medical devices, diagnostics and data science.
With locations in Minneapolis and the Washington, D.C. area, Vensana was co-founded by Versant’s Kirk Nielsen and New Enterprise Associates’ Justin Klein, who between them have helped gather more than $1 billion in capital raises for healthcare startups and supported the development of nearly three-dozen FDA-approved products.
Image: Versant's former medtech practice leader Kirk Nielsen (left) and NEA's Justin Klein, M.D., J.D., (right) will serve as Vensana's co-founders and managing partners. (Image: Vensana)
